Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
AstraZeneca LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +50.00p +0.79% 6,418.00p 6,417.00p 6,419.00p 6,467.00p 6,373.00p 6,373.00p 710,943 15:04:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 17,322.1 1,562.8 133.3 50.1 81,291.26

AstraZeneca Set for Growth in 2019 -- Earnings Review

14/02/2019 10:54am

Dow Jones News


AstraZeneca (LSE:AZN)
Historical Stock Chart

2 Months : From Jan 2019 to Mar 2019

Click Here for more AstraZeneca Charts.
   By Carlo Martuscelli 
 

AstraZeneca PLC (AZN.LN) reported its fourth-quarter and full-year results on Thursday, sending shares higher after it guided for growth in the year ahead.

 

REVENUE: The drugmaker said revenue rose 11% to $6.42 billion in the quarter ended Dec. 31, ahead of analysts' expectations of $6.32 billion, based on a FactSet consensus forecast.

 

CORE EPS: AstraZeneca reported that core earnings per share--a closely-watched company measure that strips out exceptional items--increased 22% to $1.58 in the fourth quarter. This beat analysts' expectations of $1.48.

 

WHAT WE WATCHED:

The company reported a 19% decrease in core EPS in the full year to $3.46. However, Astra said it sees a return to growth in 2019, forecasting core EPS in the range of $3.50 to $3.70. Product sales are also set to increase by a high single-digit percentage, it said.

The pharmaceutical major is benefiting from a strong portfolio of cancer drugs. Sales of Tagrisso--a targeted treatment for non-small-cell lung carcinomas--nearly doubled in the fourth quarter to $594 million. Other new cancer drugs such as Imfinzi and Lynparza are also netting the company hundreds of million of dollars in sales.

Strong sales in China have provided a further tailwind to earnings. Product sales in the country increased 22% at constant exchange rates to $948 million in the quarter.

 

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

 

(END) Dow Jones Newswires

February 14, 2019 05:39 ET (10:39 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year AstraZeneca Chart

1 Year AstraZeneca Chart

1 Month AstraZeneca Chart

1 Month AstraZeneca Chart
Your Recent History
LSE
AZN
AstraZenec..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190320 15:19:39